Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.
Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.
Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.
Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.
Kari B. Wisinski, MD, highlights modern day approaches for treating patients with metastatic triple-negative breast cancer.
Although the therapeutic utility of lymphadenectomy is uncertain, it continues to provide information for staging and helps to guide postoperative adjuvant treatment for patients with endometrial cancer.
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.